Morgan Stanley’s LumiraDx Limited Warrant LMDXW Stock Holding History

Morgan Stanley’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,454	Closed	-$64	–	8121
2023 Q4	$64	Buy	7,454 +3,727	+100%	+$55	﹤0.01%	7608
2023 Q3	$108	Hold	3,727	–	–	﹤0.01%	7437
2023 Q2	$56	Hold	3,727	–	–	﹤0.01%	7533
2023 Q1	$224	Hold	3,727	–	–	﹤0.01%	7508
2022 Q4	$220	Sell	3,727 -179,664	-98%	-$24.5K	﹤0.01%	7636
2022 Q3	$20K	Sell	183,391 -4,494	-2%	-$1.49K	﹤0.01%	6806
2022 Q2	$169K	Hold	187,885	–	–	﹤0.01%	5981
2022 Q1	$164K	Hold	187,885	–	–	﹤0.01%	6028
2021 Q4	$340K	Buy	187,885 +184,158	+4,941%	+$297K	﹤0.01%	5775
2021 Q3	$4K	Buy	+3,727	New	+$4.32K	﹤0.01%	7565

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Morgan Stanley's LMDXW Position: Q1 2024 in Review

Morgan Stanley sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 7,454 shares — an estimated $64 sold.

Morgan Stanley first reported a position in LMDXW in Q3 2021 and held it in 10 quarters. The position peaked at $340K in Q4 2021. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Morgan Stanley reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 7,454 LumiraDx Limited Warrant shares in Q1 2024, an estimated $64.
Morgan Stanley first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 10 quarters.
Morgan Stanley's LumiraDx Limited Warrant position peaked at $340K in Q4 2021.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.